08:34 AM EDT, 07/10/2024 (MT Newswires) -- Virpax Pharmaceuticals ( VRPX ) on Wednesday reported positive results in a swine model pilot study of Probudur, the company's liposomal bupivacaine formulation to provide both immediate and extended pain relief.

Probudur was injected into four juvenile domestic pigs at a dose of 30 mg per kilogram and was well-tolerated and "demonstrated a long-term, slow-release profile," the company said.

Probudur is a non-narcotic local anesthetic that prevents pain signals from reaching the brain, the company said.

Virpax shares were 46% higher in premarket trading.

Price: 1.6800, Change: +0.52, Percent Change: +44.83